Premium
Posttreatment interleukin‐2 in patients with acute myeloid leukemia: The end of a long road for patients and clinical trials?
Author(s) -
Grosso Dolores,
Weiss Mark A.
Publication year - 2013
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.28514
Subject(s) - medicine , myeloid leukemia , clinical trial , oncology , myeloid , leukemia , interleukin , intensive care medicine , cytokine
For over 2 decades, a series of clinical trials has tested the efficacy of interleukin‐2 as postremission therapy for patients with acute myeloid leukemia. In this issue, Kolitz et al describe a large clinical trial testing this hypothesis that ultimately failed to answer the question because of patients failing to complete the prescribed therapy.